{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T17:09:53Z","timestamp":1758042593904,"version":"3.44.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.bone.2020.115299","type":"journal-article","created":{"date-parts":[[2020,2,22]],"date-time":"2020-02-22T02:42:42Z","timestamp":1582339362000},"page":"115299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["No decrease in fracture risk despite 15\u202fyears of treatment evolution for multiple myeloma patients: A Danish nationwide case-control study"],"prefix":"10.1016","volume":"134","author":[{"given":"Berdien E.","family":"Oortgiesen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna H.M.","family":"Driessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mels","family":"Hoogendoorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robby E.","family":"Kibbelaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nic J.G.M.","family":"Veeger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joop P.W.","family":"van den Bergh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Vestergaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3837-8319","authenticated-orcid":false,"given":"Frank","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric N.","family":"van Roon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2020.115299_bb0005","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2020.115299_bb0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-9966-27-11","article-title":"Effect of pathologic fractures on survival in multiple myeloma patients: a case control study","volume":"27","author":"Sonmez","year":"2008","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bone.2020.115299_bb0015","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/bjh.14815","article-title":"Increased fracture risk in plasma cell dyscrasias is associated with poorer overall survival","volume":"179","author":"McIlroy","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bone.2020.115299_bb0020","article-title":"Bisphosphonates in multiple myeloma: an updated network meta-analysis","volume":"12","author":"Mhaskar","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bone.2020.115299_bb0025","doi-asserted-by":"crossref","first-page":"597,602.e1","DOI":"10.1016\/j.clml.2018.06.002","article-title":"Bone health and survival in women with multiple myeloma","volume":"18","author":"Rosko","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.bone.2020.115299_bb0030","article-title":"Fractures and survival in multiple myeloma: results from a population-based study","author":"Thorsteinsdottir","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.bone.2020.115299_bb0035","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1359\/JBMR.041131","article-title":"Fracture risk with multiple myeloma: a population-based study","volume":"20","author":"Melton","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115299_bb0040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1359\/jbmr.0301212","article-title":"Fracture risk in monoclonal gammopathy of undetermined significance","volume":"19","author":"Melton","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115299_bb0045","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-2141.2006.06269.x","article-title":"Fracture risk in patients with monoclonal gammopathy of undetermined significance","volume":"135","author":"Gregersen","year":"2006","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bone.2020.115299_bb0050","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1182\/blood-2010-04-282848","article-title":"Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study","volume":"116","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bone.2020.115299_bb0055","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1038\/bcj.2015.71","article-title":"Factors associated with an increased risk of vertebral fracture in monoclonal gammopathies of undetermined significance","volume":"5","author":"Piot","year":"2015","journal-title":"Blood Cancer. J."},{"key":"10.1016\/j.bone.2020.115299_bb0060","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","article-title":"Use of oral corticosteroids and risk of fractures","volume":"15","author":"Van Staa","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115299_bb0065","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11657-018-0424-x","article-title":"Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study","volume":"13","author":"Amiche","year":"2018","journal-title":"Arch. Osteoporos."},{"key":"10.1016\/j.bone.2020.115299_bb0070","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma aredia study group","volume":"334","author":"Berenson","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2020.115299_bb0075","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Multiple Myeloma (010) study investigators, Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2020.115299_bb0080","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1182\/blood-2010-03-275800","article-title":"Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone","volume":"116","author":"Harousseau","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bone.2020.115299_bb0085","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/bjh.15095","article-title":"Effect of low-dose bortezomib on bone formation in smouldering multiple myeloma","volume":"184","author":"Hildebrandt","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bone.2020.115299_bb0090","first-page":"462","article-title":"Bone building with bortezomib","volume":"118","author":"Roodman","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2020.115299_bb0095","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ajh.21310","article-title":"The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo","volume":"84","author":"Pennisi","year":"2009","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bone.2020.115299_bb0100","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1600-0609.2010.01523.x","article-title":"Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma","volume":"86","author":"Lee","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.bone.2020.115299_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2012.11.005","article-title":"Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL\/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules","volume":"41","author":"Bolzoni","year":"2013","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.bone.2020.115299_bb0110","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/leu.2008.174","article-title":"Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma","volume":"22","author":"Breitkreutz","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bone.2020.115299_bb0115","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/1403494810394718","article-title":"The danish national health service register","volume":"39","author":"Andersen","year":"2011","journal-title":"Scand. J. Public Health."},{"key":"10.1016\/j.bone.2020.115299_bb0120","first-page":"263","article-title":"The danish national hospital register. A valuable source of data for modern health sciences","volume":"46","author":"Andersen","year":"1999","journal-title":"Dan. Med. Bull."},{"key":"10.1016\/j.bone.2020.115299_bb0125","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1126\/science.287.5462.2398","article-title":"Epidemiology. When an entire country is a cohort","volume":"287","author":"Frank","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.bone.2020.115299_bb0130","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/oxfordjournals.aje.a116396","article-title":"Selection of controls in case-control studies. I. Principles","volume":"135","author":"Wacholder","year":"1992","journal-title":"Am. J. Epidemiol."},{"author":"European Medicines Agency","key":"10.1016\/j.bone.2020.115299_bb0135"},{"author":"European Medicines Agency","key":"10.1016\/j.bone.2020.115299_bb0140"},{"author":"European Medicines Agency","key":"10.1016\/j.bone.2020.115299_bb0145"},{"key":"10.1016\/j.bone.2020.115299_bb0150","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1046\/j.1365-2141.2001.03206.x","volume":"115","year":"2001","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bone.2020.115299_bb0155","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1365-2141.2005.05867.x","article-title":"Guidelines on the diagnosis and management of multiple myeloma 2005","volume":"132","author":"Smith","year":"2006","journal-title":"Br. J. Haematol."},{"year":"2011","series-title":"Diagnostik og behandling af myelomatose. 2019","author":"Danish Myeloma Study Group","key":"10.1016\/j.bone.2020.115299_bb0160"},{"key":"10.1016\/j.bone.2020.115299_bb0165","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.bone.2020.115299_bb0170","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/qjmed\/hci029","article-title":"A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids","volume":"98","author":"van Staa","year":"2005","journal-title":"QJM"},{"key":"10.1016\/j.bone.2020.115299_bb0175","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/BSD.0b013e318260a076","article-title":"Functional outcomes and height restoration for patients with multiple myeloma-related osteolytic vertebral compression fractures treated with kyphoplasty","volume":"27","author":"Julka","year":"2014","journal-title":"J. Spinal Disord. Tech."},{"key":"10.1016\/j.bone.2020.115299_bb0180","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.spinee.2015.05.026","article-title":"Radiologic and clinical characteristics of vertebral fractures in multiple myeloma","volume":"15","author":"Miller","year":"2015","journal-title":"Spine J."},{"key":"10.1016\/j.bone.2020.115299_bb0185","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.spinee.2015.12.014","article-title":"Predicting the progression of vertebral fractures in patients with multiple myeloma","volume":"16","author":"Xiao","year":"2016","journal-title":"Spine J."},{"key":"10.1016\/j.bone.2020.115299_bb0190","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/jbmr.2443","article-title":"Association of QCT bone mineral density and bone structure with vertebral fractures in patients with multiple myeloma","volume":"30","author":"Borggrefe","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115299_bb0195","first-page":"10","article-title":"Surgery for vertebral involvement in multiple myeloma","volume":"62","author":"Donnarumma","year":"2018","journal-title":"J. Neurosurg. Sci."},{"key":"10.1016\/j.bone.2020.115299_bb0200","doi-asserted-by":"crossref","first-page":"11081","DOI":"10.1007\/s13277-016-4963-8","article-title":"Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials","volume":"37","author":"Gao","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.bone.2020.115299_bb0205","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bone.2020.115299_bb0210","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11914-018-0464-6","article-title":"Current understanding of epidemiology, pathophysiology, and management of atypical femur fractures","volume":"16","author":"Starr","year":"2018","journal-title":"Curr. Osteoporos Rep."},{"key":"10.1016\/j.bone.2020.115299_bb0215","first-page":"2833","article-title":"Patterns of bisphosphonate treatment among patients with multiple myeloma treated at oncology clinics across the USA: observations from real-world data","volume":"26","author":"Kim","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bone.2020.115299_bb0220","doi-asserted-by":"crossref","first-page":"22","DOI":"10.6004\/jnccn.2018.7079","article-title":"Use of bisphosphonates in elderly patients with newly diagnosed multiple myeloma","volume":"17","author":"Leng","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.bone.2020.115299_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20010083","article-title":"Anabolic therapies in osteoporosis and bone regeneration","volume":"20","author":"Russow","year":"2018","journal-title":"Int. J. Mol. Sci."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632822030079X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632822030079X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:46:27Z","timestamp":1757612787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S875632822030079X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":45,"alternative-id":["S875632822030079X"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2020.115299","relation":{},"ISSN":["8756-3282"],"issn-type":[{"type":"print","value":"8756-3282"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No decrease in fracture risk despite 15\u202fyears of treatment evolution for multiple myeloma patients: A Danish nationwide case-control study","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2020.115299","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115299"}}